1
|
Mantziari S, Abboretti F, Favre L, Thomopoulos T, Barigou M, Demartines N, Suter M. Protein malnutrition after Roux-en-Y gastric bypass: a challenging case and scoping review of the literature. Surg Obes Relat Dis 2023; 19:746-754. [PMID: 36702647 DOI: 10.1016/j.soard.2022.12.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Revised: 12/10/2022] [Accepted: 12/17/2022] [Indexed: 12/29/2022]
Abstract
Although protein malnutrition (PM) is often reported after highly malabsorptive procedures, its exact incidence and mechanisms after Roux-en-Y gastric bypass (RYGB) are poorly understood. The aim of this study was to present a challenging clinical case of PM after RYGB and conduct a scoping review of the literature. Among the 18 studies with 3015 RYGB patients included in the review, the median incidence of PM was 1.7% (range, 0%-8.9%), and it was diagnosed 12 to 120 months after RYGB. The most common cause is insufficient oral intake of protein; however, in cases of persistent hypoalbuminemia, a thorough diagnostic workup needs to be performed. Risk factors for PM after RYGB include specific triggering events such as intractable vomiting and dysphagia, and a total alimentary limb length less than 250 to 300 cm.
Collapse
Affiliation(s)
- Styliani Mantziari
- Department of Visceral Surgery, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculty of Biology and Medicine, Lausanne University (UNIL), Lausanne, Switzerland
| | - Francesco Abboretti
- Department of Visceral Surgery, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculty of Biology and Medicine, Lausanne University (UNIL), Lausanne, Switzerland
| | - Lucie Favre
- Faculty of Biology and Medicine, Lausanne University (UNIL), Lausanne, Switzerland; Division of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Theodoros Thomopoulos
- Department of Visceral Surgery, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Mohammed Barigou
- Division of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - Nicolas Demartines
- Department of Visceral Surgery, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculty of Biology and Medicine, Lausanne University (UNIL), Lausanne, Switzerland
| | - Michel Suter
- Department of Visceral Surgery, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Faculty of Biology and Medicine, Lausanne University (UNIL), Lausanne, Switzerland; Department of Surgery, Riviera-Chablais Hospital, Rennaz, Switzerland.
| |
Collapse
|
2
|
Fatemeh G, Fotsing G, Marques-Vidal P, Kopp P, Barigou M. Predictive value of multiple variable models including nutritional risk score (NRS 2002) on mortality and length of stay of patients with covid-19 infections. The INCOVO study. Clin Nutr ESPEN 2023; 55:357-363. [PMID: 37202068 DOI: 10.1016/j.clnesp.2023.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 04/01/2023] [Indexed: 05/20/2023]
Abstract
BACKGROUND AND AIMS This study aimed at evaluating associations between nutritional status and outcomes in patients with Covid-19 and to identify statistical models including nutritional parameters associated with in-hospital mortality and length of stay. METHODS Data of 5707 adult patients hospitalized in the University Hospital of Lausanne between March 2020 and March 2021 were screened retrospectively 920 patients (35% female) with confirmed Covid-19 and complete data including nutritional risk score (NRS 2002), were included. This cohort was divided into three subgroups: NRS <3: no risk of malnutrition; NRS ≥3 to <5: moderate risk malnutrition; and NRS ≥5: severe risk of malnutrition. The primary outcome was the percentage of in-hospital deaths in the different NRS subgroups. The secondary outcomes were the length of hospital stay (LOS), the percentage of admissions to intensive care units (ICU), and the length of stay in the ICU (ILOS). Logistic regression was performed to identify risk factors associated with in-hospital mortality and hospital stay. Multivariate clinical-biological models were developed to study predictions of mortality and very long length of stay. RESULTS The mean age of the cohort was 69.7 years. The death rate was 4 times higher in the subgroup with a NRS ≥ 5 (44%), and 3 times higher with a NRS ≥ 3 to <5 (33%) compared to the patients with a NRS<3 (10%) (p < 0.001). LOS was significantly higher in the NRS ≥ 5 and NRS ≥ 3 to <5 subgroups (26.0 days; CI [21; 30.9]; and 24.9; CI [22.5; 27.1] respectively) versus 13.4; CI [12; 14.8] for NRS<3 (p < 0.001). The mean ILOS was significantly higher in the NRS ≥ 5 (5.9 days; versus 2.8 for NRS ≥ 3 to <5, and 1.58 for NRS<3 (p < 0.001)). In logistic regression, NRS ≥ 3 was significantly associated with the risk of mortality (OR: 4.8; CI [3.3; 7.1]; p < 0.001) and very long in-hospital stay (>12 days) (OR: 2.5; CI [1.9; 3.3]; p < 0.001). Statistical models that included a NRS ≥ 3 and albumin revealed to be strong predictors for mortality and LOS (area under the curve 0.800 and 0.715). CONCLUSION NRS was found to be an independent risk factor for in-hospital death and LOS in hospitalized Covid-19 patients. Patients with a NRS ≥ 5 had a significant increase in ILOS and mortality. Statistical models including NRS are strong predictors for an increased risk of death and LOS.
Collapse
Affiliation(s)
- Ghadamieh Fatemeh
- Division of Endocrinology, Diabetology and Metabolism, University Hospital of Lausanne and University of Lausanne, Avenue de la Sallaz 8, 1011 Lausanne, Switzerland; School of Life Sciences, Ecole Polytechnique fédérale de Lausanne, SV, Station 19, 1015 Lausanne, Switzerland.
| | - Ginette Fotsing
- Division of Endocrinology, Diabetology and Metabolism, University Hospital of Lausanne and University of Lausanne, Avenue de la Sallaz 8, 1011 Lausanne, Switzerland.
| | - Pedro Marques-Vidal
- Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland.
| | - Peter Kopp
- Division of Endocrinology, Diabetology and Metabolism, University Hospital of Lausanne and University of Lausanne, Avenue de la Sallaz 8, 1011 Lausanne, Switzerland.
| | - Mohammed Barigou
- Division of Endocrinology, Diabetology and Metabolism, University Hospital of Lausanne and University of Lausanne, Avenue de la Sallaz 8, 1011 Lausanne, Switzerland.
| |
Collapse
|
3
|
Pannatier J, Fotsing G, Pitteloud N, Barigou M. Predictive Value Of Bia Parameters On Menses Recovery In Patients With Anorexia Nervosa. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
4
|
Santini S, Vionnet N, Barigou M, Pasquier J, Favre L. Is prealbumine a good biomarker of lean mass loss after gastric bypass? Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
5
|
Tankeu AT, Barigou M, Pedro R, De Micheli R, Bodmer A, Genton L, Collet TH, Tran C. [Is ketogenic diet effective against cancer ?]. Rev Med Suisse 2023; 19:576-580. [PMID: 36950789 DOI: 10.53738/revmed.2023.19.819.576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]
Abstract
The ketogenic diet, which consists of reduced carbohydrate intake and increased fat intake, is a recognized treatment option for children with intractable epilepsy. This diet is now receiving renewed interest from physicians and researchers because of its potential therapeutic effect in other diseases, such as neurodegenerative diseases, metabolic syndrome or cancer. Since cancer is one of the major public health challenges, complementary approaches to improve the efficacy of standard anti-cancer therapies are the subject of much research. This article reviews the place of the ketogenic diet as a complementary therapy in cancer, the scientific evidence and possible practical aspects of such an approach.
Collapse
Affiliation(s)
- Aurel T Tankeu
- Service de médecine génétique, Centre des maladies moléculaires, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Mohammed Barigou
- Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Rosette Pedro
- Diététicienne, Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Rita De Micheli
- Département d'oncologie, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Alexandre Bodmer
- Service d'oncologie médicale - Centre du sein, Département d'oncologie, Hôpitaux universitaires de Genève, 1211 Genève 14
| | - Laurence Genton
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique, Hôpitaux universitaires de Genève, 1211 Genève 14
- Faculté de médecine, Université de Genève, 1204 Genève
| | - Tinh-Hai Collet
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique, Hôpitaux universitaires de Genève, 1211 Genève 14
- Centre facultaire du diabète, Faculté de médecine, Université de Genève, 1204 Genève
| | - Christel Tran
- Service de médecine génétique, Centre des maladies moléculaires, Centre hospitalier universitaire vaudois, 1011 Lausanne
- Unité de nutrition, Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique, Hôpitaux universitaires de Genève, 1211 Genève 14
| |
Collapse
|
6
|
Pinto Almeida M, Fotsing G, Gijs E, Barigou M. [Clinical nutrition: what's new in 2022]. Rev Med Suisse 2023; 19:46-51. [PMID: 36660837 DOI: 10.53738/revmed.2023.19.809-10.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In 2022, the European Society of Enteral and Parenteral Nutrition (ESPEN) has released several relevant updates and guidelines. This review will highlight the key messages of three guidelines focusing on nutritional management in the geriatric population, micronutrient disorders, and sarcopenic obesity. Special emphasis will be directed towards recommendations impacting ambulatory clinical practice.
Collapse
Affiliation(s)
- Monica Pinto Almeida
- Service d'endocrinologie diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Ginette Fotsing
- Service d'endocrinologie diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Elise Gijs
- Service d'endocrinologie diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Mohammed Barigou
- Service d'endocrinologie diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne
| |
Collapse
|
7
|
Del Giorno R, Keller S, Barigou M, Buso G, Mazzolai L. [Subclinical atherosclerosis in hypercholesterolemia - Towards a personalized, shared decision-making cardiovascular prevention]. Rev Med Suisse 2021; 17:2117-2122. [PMID: 34878738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Identification of subjects at increased cardiovascular risk (CV) using traditional risk calculators is established. Nevertheless, up to 50% of CV events occur in people classified as intermediate risk. Non-invasive atherosclerosis (ATS) assessment with carotid/femoral US and coronary artery calcium score, offers the opportunity of a personalized prevention. ATS detection could be useful in improving CV risk stratification, in optimizing individual therapeutic management and in promoting a shared decision-making process. Is this the era of a paradigm shift in CV-risk prediction? The fascinating question is still open, but the increasing number of evidences shed new insights for our everyday clinical practice. Here we strive to provide an updated scenario on the use of ATS imaging in the CV risk evaluation and therapeutic decision.
Collapse
Affiliation(s)
- Rosaria Del Giorno
- Service d'angiologie, Département cœur-vaisseaux, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Sanjiv Keller
- Service d'angiologie, Département cœur-vaisseaux, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Mohammed Barigou
- Service d'endocrinologie, diabétologie et métabolisme, Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Giacomo Buso
- Service d'angiologie, Département cœur-vaisseaux, Centre hospitalier universitaire vaudois, 1011 Lausanne
| | - Lucia Mazzolai
- Service d'angiologie, Département cœur-vaisseaux, Centre hospitalier universitaire vaudois, 1011 Lausanne
| |
Collapse
|
8
|
Kulkarni S, Dominiczak AF, Touyz RM, Spence JD, Batlle D, Barigou M, Brown M, Carey RM, Elijovich F, Taler S, Wilkinson IB. CONNed in Pregnancy. Hypertension 2021; 78:241-249. [PMID: 34058849 DOI: 10.1161/hypertensionaha.121.17021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Spoorthy Kulkarni
- From the Cambridge University hospitals NHS foundation trust, Cambridge United Kingdom (S.K.)
| | - Anna F Dominiczak
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences (A.F.D.), University of Glasgow, United Kingdom
| | - Rhian M Touyz
- Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre (R.M.T.), University of Glasgow, United Kingdom
| | - J David Spence
- Stroke Prevention & Atherosclerosis Research Centre, Western University, London, Ontario, Canada (J.D.S.)
| | - Daniel Batlle
- Division of Nephrology and Hypertension, Northwestern University Feinberg Medical School, Chicago, IL (D.B.)
| | - Mohammed Barigou
- Endocrinology diabetes and metabolism division, Lausanne University hospital (CHUV), Switzerland (M. Barigou)
| | - Morris Brown
- The Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, United Kingdom Clinical Pharmacology Unit (M. Brown)
| | - Robert M Carey
- Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville (R.M.C.)
| | - Fernando Elijovich
- Department of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN (F.E.)
| | - Sandra Taler
- Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN (S.T.)
| | - Ian B Wilkinson
- Division of Experimental Medicine and Immuno-therapeutics, University of Cambridge, United Kingdom (I.B.W.)
| |
Collapse
|
9
|
Clark D, Dominiczak AF, Touyz RM, Barigou M, Zoghby Z, Jones DW. Woman With Polycystic Kidney Disease: The Role of Precision Medicine in Hypertension Management. Hypertension 2020; 76:1332-1338. [PMID: 32951469 DOI: 10.1161/hypertensionaha.120.15021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Donald Clark
- From the Department of Medicine (D.C., D.W.J.), University of Mississippi Medical Center, Jackson
| | - Anna F Dominiczak
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences (A.F.D.), University of Glasgow, United Kingdom
| | - Rhian M Touyz
- Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre (R.M.T.), University of Glasgow, United Kingdom
| | - Mohammed Barigou
- Endocrinology Diabetes and Metabolism Division, CHU Vaudois, Lausanne, Switzerland (M.B.)
| | - Ziad Zoghby
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine, MN (Z.Z.)
| | - Daniel W Jones
- From the Department of Medicine (D.C., D.W.J.), University of Mississippi Medical Center, Jackson
- Department of Physiology and Biophysics (D.W.J.), University of Mississippi Medical Center, Jackson
| |
Collapse
|
10
|
Gallacher PJ, Farrah TE, Dominiczak AF, Touyz RM, Adamczak M, Barigou M, Zoghby Z, Hiremath S, Dhaun N. Resistant Hypertension in a Dialysis Patient. Hypertension 2020; 76:278-287. [PMID: 32594796 DOI: 10.1161/hypertensionaha.120.15022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Peter J Gallacher
- From the Department of Renal Medicine, Royal Infirmary of Edinburgh (P.J.G., T.E.F., N.D.).,University/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh (P.J.G., T.E.F., N.D.)
| | - Tariq E Farrah
- From the Department of Renal Medicine, Royal Infirmary of Edinburgh (P.J.G., T.E.F., N.D.).,University/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh (P.J.G., T.E.F., N.D.)
| | - Anna F Dominiczak
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences (A.F.D.), University of Glasgow, United Kingdom
| | - Rhian M Touyz
- Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre (R.M.T.), University of Glasgow, United Kingdom
| | - Marcin Adamczak
- Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland (M.A.)
| | - Mohammed Barigou
- Endocrinology Diabetes and Metabolism Division, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (M.B.)
| | - Ziad Zoghby
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN (Z.Z.)
| | - Swapnil Hiremath
- Division of Nephrology, Department of Medicine, University of Ottawa, Canada (S.H.)
| | - Neeraj Dhaun
- From the Department of Renal Medicine, Royal Infirmary of Edinburgh (P.J.G., T.E.F., N.D.).,University/British Heart Foundation Centre of Research Excellence, Centre of Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh (P.J.G., T.E.F., N.D.)
| |
Collapse
|
11
|
Barigou M, Favre L, Fraga M, Artru F. [New trends in non-alcoholic fatty liver diseases (NAFLD)]. Rev Med Suisse 2020; 16:586-591. [PMID: 32216182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases with an epidemiology correlated to obesity and metabolic syndrome. The last decade was rich of significant advances in understanding the pathophysiology of the disease, linking environmental elements, genetic factors and microbiota modifications, as well as in staging, screening and therapeutic development. The purpose of this article is to summarize recent advances in the field of NAFLD, on her way to become the first cause of cirrhosis and liver transplantation worldwide.
Collapse
Affiliation(s)
- Mohammed Barigou
- Service d'endocrinologie, diabétologie et métabolisme, CHUV, 1011 Lausanne
| | - Lucie Favre
- Service d'endocrinologie, diabétologie et métabolisme, CHUV, 1011 Lausanne
| | - Montserrat Fraga
- Service de gastroentérologie et hépatologie, CHUV, 1011 Lausanne
| | - Florent Artru
- Service de gastroentérologie et hépatologie, CHUV, 1011 Lausanne
| |
Collapse
|
12
|
van Twist DJL, de Leeuw PW, Spiering W, Rossi GP, Dominiczak AF, Jennings GLR, Barigou M, Persu A, Kroon AA. Unifocal and Multifocal Fibromuscular Dysplasia. Hypertension 2019; 73:7-12. [PMID: 30571541 DOI: 10.1161/hypertensionaha.118.12004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Daan J L van Twist
- From the Department of Internal Medicine, Zuyderland Medical Centre, Sittard/Heerlen, the Netherlands (D.J.L.v.T, P.W.d.L.)
| | - Peter W de Leeuw
- From the Department of Internal Medicine, Zuyderland Medical Centre, Sittard/Heerlen, the Netherlands (D.J.L.v.T, P.W.d.L.).,Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, the Netherlands (P.W.d.L., A.A.K.)
| | - Wilko Spiering
- Department of Vascular Medicine, University Medical Center Utrecht, the Netherlands (W.S.)
| | - Gian Paolo Rossi
- Department of Medicine, Hypertension Unit, University of Padova, Italy (G.P.R.)
| | - Anna F Dominiczak
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D.)
| | - Garry L R Jennings
- Sydney Health Partners, Sydney Medical School, University of Sydney, New South Wales, Australia (G.L.R.J.)
| | - Mohammed Barigou
- Assistance Publique-Hôpitaux de Paris, Hypertension Unit, Hospital European Georges Pompidou, University Paris Descartes, France (M.B.)
| | - Alexandre Persu
- Department of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium (A.P.).,Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium (A.P.)
| | - Abraham A Kroon
- Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, the Netherlands (P.W.d.L., A.A.K.)
| |
Collapse
|
13
|
Kouadio A, Guex E, Barigou M, Coti Bertrand P. SUN-PO034: Prevalence of Obese Older Malnourished Adults and Coverage of Their Protein Needs in a Tertiary Center. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32668-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Abstract
We investigate the existence and stability of bulk nanobubbles in various aqueous organic solvent mixtures. Bulk nanobubble suspensions generated via acoustic cavitation are characterized in terms of their bubble size distribution, bubble number density, and zeta potential. We show that bulk nanobubbles exist in pure water but do not exist in pure organic solvents, and they disappear at some organic solvent-water ratio. We monitor the nanobubble suspensions over a period of a few months and propose interpretations for the differences behind their long-term stability in pure water versus their long-term stability in aqueous organic solvent solutions. Bulk nanobubbles in pure water are stabilized by their substantial surface charge arising from the adsorption of hydroxyl ions produced by self-ionization of water. Pure organic solvents do not autoionize, and therefore, nanobubbles cannot exist in concentrated aqueous organic solvent solutions. Because of preferential adsorption of organic solvent molecules at the nanobubble interfaces, the surface charge of the nanobubbles decreases with the solvent content, but the strong hydrogen bonding near their interfaces ensures their stability. The mean bubble size increases monotonically with the solvent content, whereas the surface tension of the mixture is sharply reduced. This is in agreement with literature results on macro- and microbubbles in aqueous organic solutions, but it stands in stark contrast to the behavior of macro- and microbubbles in aqueous surfactant solutions.
Collapse
Affiliation(s)
- N Nirmalkar
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| | - A W Pacek
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| | - M Barigou
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| |
Collapse
|
15
|
Abstract
This paper elucidates parts of the mystery behind the interfacial and colloidal stability of the novel bubble system of bulk nanobubbles. Stable bulk nanobubble suspensions have been generated in pure water using hydrodynamic cavitation in a high-pressure microfluidic device. The effects of pH adjustment, addition of different types of surfactant molecules and salts on the nanobubble suspensions have been studied. Results show that nanobubble interfaces in pure water are negatively charged, suggesting the formation of an electric double layer around the nanobubbles. It is presumed that the external electrostatic pressure created by the charged nanobubble interface, balances the internal Laplace pressure; therefore, no net diffusion of gas occurs at equilibrium and the nanobubbles are stable. Such stability increases with increasing alkalinity of the suspending medium. The addition of mono- and multi-valent salts leads to the screening of the electric double layer, hence, destabilizing the nanobubbles. Different surfactant molecules (non-ionic, anionic, cationic) affect the stability of bulk nanobubbles in different ways. Calculations based on the DLVO theory predict a stable colloidal system for bulk nanobubbles in pure water and this could be a further reason for their observed longevity. All in all, in pure water, the long-term stability of bulk nanobubbles seems to be caused by a combination of ion-stabilisation of their interface against dissolution and colloidal stability of the suspension.
Collapse
Affiliation(s)
- N Nirmalkar
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
| | | | | |
Collapse
|
16
|
Abstract
Bulk nanobubbles are a novel type of nanoscale bubble system. Because of their extraordinary behavior, however, their existence is not widely accepted. In this paper, we shed light on the hypothesis that bulk nanobubbles do exist, they are filled with gas, and they survive for long periods of time, challenging present theories. An acoustic cavitation technique has been used to produce bulk nanobubbles in pure water in relatively large numbers approaching 109 bubble·mL-1 with a typical diameter of 100-120 nm. We provide multiple evidence that the nanoentities observed in suspension are nanobubbles given that they disappear after freezing and thawing of the suspensions, their nucleation rate depends strongly on the amount of air dissolved in water, and they gradually disappear over time. The bulk nanobubble suspensions were stable over periods of many months during which time the mean diameter remained unchanged, suggesting the absence of significant bubble coalescence, bubble breakage, or Ostwald ripening effects. Measurements suggest that these nanobubbles are negatively charged and their zeta potential does not vary over time. The presence of such a constant charge on the nanobubble surfaces is probably responsible for their stability. The effects of pH, salt, and surfactant addition on their colloidal stability are similar to those reported in the literature for solid nanoparticle suspensions, that is, nanobubbles are more stable in an alkaline medium than in an acidic one; the addition of salt to a nanobubble suspension drives the negative zeta potential toward zero, thus reducing the repulsive electrostatic forces between nanobubbles; and the addition of an anionic surfactant increases the magnitude of the negative zeta potential, thus improving nanobubble electrostatic stabilization.
Collapse
Affiliation(s)
- N Nirmalkar
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| | - A W Pacek
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| | - M Barigou
- School of Chemical Engineering , University of Birmingham , Edgbaston , Birmingham B15 2TT , U.K
| |
Collapse
|
17
|
George MJ, Marks DJB, Rezk T, Breckenridge R, Sofat R, Martin J, MacAllister R, Touyz RM, Staessen JA, Bursztyn M, Lappin D, Barigou M, Hingorani A. Resistant Hypertension: Trials and Tribulations. Hypertension 2018; 71:772-780. [PMID: 29610269 DOI: 10.1161/hypertensionaha.118.10864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Marc J George
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Daniel J B Marks
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Tamer Rezk
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Ross Breckenridge
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Reecha Sofat
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - John Martin
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Raymond MacAllister
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Rhian M Touyz
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Jan A Staessen
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Michael Bursztyn
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - David Lappin
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Mohammed Barigou
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| | - Aroon Hingorani
- From the Department of Clinical Pharmacology, University College London Hospital NHS Foundation Trust, United Kingdom (M.J.G., R.S., J.M., A.H.); Centre for Molecular Medicine, University College London, United Kingdom (D.J.B.M.); Nephrology, Royal Free London NHS Foundation Trust, United Kingdom (T.R.); Silver Creek Pharmaceuticals, San Francisco, CA (R.B.); Dorset County Hospital, Dorchester, United Kingdom (R.M.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (R.M.T.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.); Hadassah-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Israel (M.B.); Department of Nephrology, Galway University Hospitals, Ireland (D.L.); and University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (M.B.)
| |
Collapse
|
18
|
Ariane M, Wen W, Vigolo D, Brill A, Nash FGB, Barigou M, Alexiadis A. Modelling and simulation of flow and agglomeration in deep veins valves using discrete multi physics. Comput Biol Med 2017; 89:96-103. [PMID: 28797741 DOI: 10.1016/j.compbiomed.2017.07.020] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 07/10/2017] [Accepted: 07/28/2017] [Indexed: 11/30/2022]
Abstract
The hemodynamics in flexible deep veins valves is modelled by means of discrete multi-physics and an agglomeration algorithm is implemented to account for blood accrual in the flow. Computer simulations of a number of valves typologies are carried out. The results show that the rigidity and the length of the valve leaflets play a crucial role on both mechanical stress and stagnation in the flow. Rigid and short membranes may be inefficient in preventing blood reflux, but reduce the volume of stagnant blood potentially lowering the chances of thrombosis. Additionally, we also show that in venous valves, cell agglomeration is driven by stagnation rather than mechanical stress.
Collapse
Affiliation(s)
- M Ariane
- School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom.
| | - W Wen
- School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom
| | - D Vigolo
- School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom
| | - A Brill
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| | - F G B Nash
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| | - M Barigou
- School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom
| | - A Alexiadis
- School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom.
| |
Collapse
|
19
|
Calvet D, Amar L, Rossi GP, Laurent S, Dominiczak AF, Turc G, Barigou M, Jennings G, Guzik T, Touyz RM. Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension 2017; 69:985-991. [PMID: 28461597 DOI: 10.1161/hypertensionaha.117.09330] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- David Calvet
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.).
| | - Laurence Amar
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Gian Paolo Rossi
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Stéphane Laurent
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Anna F Dominiczak
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Guillaume Turc
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | | | - Garry Jennings
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Tomasz Guzik
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| | - Rhian M Touyz
- From the Department of Neurology, Centre Hospitalier Sainte-Anne, Université Paris Descartes, INSERM U894, DHU Neurovasc, Sorbonne Paris Cité, France (D.C., G.T.); University Paris Descartes, AP-HP, Hospital Europeen Georges Pompidou, France (L.A.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., T.G., R.M.T.); Department of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, France (S.L.); Sydney Medical School, University of Sydney, New South Wales, Australia (G.J.); and Baker Heart and Diabetes Institute, Melbourne, Australia (G.J.)
| |
Collapse
|
20
|
Amar L, Sharabi Y, Rossi GP, Vidal-Petiot E, Dominiczak AF, Mulatero P, Faucon AL, Dhaun N, Touyz RM, Barigou M, Lorthioir A. Case of Primary Aldosteronism With Discordant Hormonal and Computed Tomographic Findings. Hypertension 2017; 69:529-535. [PMID: 28193708 DOI: 10.1161/hypertensionaha.116.08751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Laurence Amar
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.).
| | - Yehonatan Sharabi
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Gian Paolo Rossi
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Emmanuelle Vidal-Petiot
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Anna F Dominiczak
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Paolo Mulatero
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Anne-Laure Faucon
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Neeraj Dhaun
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Rhian M Touyz
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Mohammed Barigou
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| | - Aurelien Lorthioir
- From the University Paris Descartes, AP-HP, Hypertension Unit, Hospital European Georges Pompidou, France (L.A., A.-L.F., M.B., A.L.); Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.); Clinica dell'Ipertensione, Department of Medicine, DIMED, University Hospital, Padova, Italy (G.P.R.); Physiology Department, DHU FIRE, Bichat Hospital, AP-HP, Inserm, University Paris Diderot, Sorbonne Paris Cité, France (E.V.P.); Institute of Cardiovascular and Medical Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D., R.M.T.); Division of Internal Medicine and Hypertension Unit, Department of Medical Science, University of Turin, Italy (P.M.); and University/BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (N.D.)
| |
Collapse
|
21
|
Alexiadis A, Stamatopoulos K, Wen W, Batchelor HK, Bakalis S, Barigou M, Simmons MJH. Using discrete multi-physics for detailed exploration of hydrodynamics in an in vitro colon system. Comput Biol Med 2017; 81:188-198. [PMID: 28088672 DOI: 10.1016/j.compbiomed.2017.01.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 12/13/2016] [Accepted: 01/07/2017] [Indexed: 11/15/2022]
Abstract
We developed a mathematical model that describes the motion of viscous fluids in the partially-filled colon caused by the periodic contractions of flexible walls (peristalsis). In-vitro data are used to validate the model. The model is then used to identify two fundamental mechanisms of mass transport: the surfing mode and the pouring mode. The first mechanism is faster, but only involves the surface of the liquid. The second mechanism causes deeper mixing, and appears to be the main transport mechanism. Based on the gained understanding, we propose a series of measures that can improve the reliability of in-vitro models. The tracer in PET-like experiments, in particular, should not be injected in the first pocket, and its viscosity should be as close as possible to that of the fluid. If these conditions are not met, the dynamics of the tracer and the fluid diverge, compromising the accuracy of the in-vitro data.
Collapse
Affiliation(s)
- A Alexiadis
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.
| | - K Stamatopoulos
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - W Wen
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - H K Batchelor
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - S Bakalis
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - M Barigou
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - M J H Simmons
- School of Chemical Engineering, University of Birmingham, Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| |
Collapse
|
22
|
Noilhan C, Barigou M, Bieler L, Amar J, Chamontin B, Bouhanick B. Causes of secondary hypertension in the young population: A monocentric study. Ann Cardiol Angeiol (Paris) 2016; 65:159-164. [PMID: 27209493 DOI: 10.1016/j.ancard.2016.04.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Accepted: 04/20/2016] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To study the prevalence of different causes of hypertension in young adults referred to a hypertension center in the south west of France. METHODS We conducted a retrospective overview of patients younger than 40years old hospitalized consecutively in the Hypertension department of Toulouse University Hospital between 2012 and 2014. Clinical data about gender, age, anthropomorphic parameters and blood pressure measurement by 24h Ambulatory Blood Pressure Monitoring (ABPM) were recorded. Biological data concerned dosages of kalemia, renin and aldosterone in the supine or after 15min of seating. Recorded radiological examinations were renal artery ultrasound and abdominal CT scan. RESULTS One hundred and forty-eight detailed medical records were analyzed, 69 women and 79 men. Among the 69 women, the causes of secondary hypertension were primary aldosteronism (n=7), fibromuscular dysplasia (n=5) and renal disease (n=4). Oral contraceptives were involved in 13 women. In addition, essential hypertension concerned 40 women (58%). Among the 79 men, the causes of secondary hypertension were primary aldosteronism (n=10), fibromuscular dysplasia (n=3), left main renal artery entrapment by a diaphragmatic crura (n=2), renal disease (n=1), pheochromocytoma (n=3) and coarctation of the aorta (n=2). In addition, essential hypertension concerned 58 men (73%). CONCLUSIONS In our population, the prevalence of secondary hypertension is close to 33% (42% of females and 27% of males), with the following main causes: primary aldosteronism for 11.5%; fibromuscular dysplasia for 5.4%. Oral contraceptives were involved in the hypertension of 19% of the females.
Collapse
Affiliation(s)
- C Noilhan
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France
| | - M Barigou
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France.
| | - L Bieler
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France
| | - J Amar
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France
| | - B Chamontin
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France
| | - B Bouhanick
- Hypertension department, Cardiovascular and metabolic center, Rangueil University Hospital, Toulouse, France
| |
Collapse
|
23
|
Ritz P, Vaurs C, Barigou M, Hanaire H. Hypoglycaemia after gastric bypass: mechanisms and treatment. Diabetes Obes Metab 2016; 18:217-23. [PMID: 26508374 DOI: 10.1111/dom.12592] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Revised: 08/01/2015] [Accepted: 10/17/2015] [Indexed: 01/07/2023]
Abstract
Hypoglycaemia after gastric bypass can be severe, but is uncommon, and is sometimes only revealed through monitoring glucose concentrations. The published literature is limited by the heterogeneity of the criteria used for diagnosis, arguing in favour of the Whipple triad with a glycaemia threshold of 55 mg/dl as the diagnostic reference. Women who lost most of their excess weight after gastric bypass, long after the surgery was performed, and who did not have diabetes before surgery are at the greatest risk. In this context, hypoglycaemia results from hyperinsulinism, which is either generated by pancreas anomalies (nesidioblastosis) and/or caused by an overstimulation of β cells by incretins, mainly glucagon-like peptide-1 (GLP-1). Glucose absorption is both accelerated and increased because of the direct communication between the gastric pouch and the jejunum. This is a post-surgical exaggeration of a natural adaptation that is seen in patients who have not undergone surgery in whom glucose is infused directly into the jejunum. There is not always a correspondence between symptoms and biological traits; however, hyperinsulinism is constant if hypoglycaemia is severe and there are neuroglucopenic symptoms. The treatment relies firstly on changes in eating habits, splitting food intake into five to six daily meals, slowing gastric emptying, reducing the glycaemic load and glycaemic index of foods, using fructose and avoiding stress at meals. Pharmacological treatment with acarbose is efficient, but other drugs still need to be validated in a greater number of subjects (insulin, glucagon, calcium channel blockers, somatostatin analogues and GLP-1 analogues). Lastly, if the surgical option has to be used, the benefits (efficient symptom relief) and the risks (weight regain, diabetes) should be weighed carefully.
Collapse
Affiliation(s)
- P Ritz
- Pôle Cardio-vasculaire et métabolique, Centre Intégré de l'obésité, Inserm U1027, CHU de Toulouse, Hôpital Larrey, Toulouse, France
| | - C Vaurs
- Pôle Cardio-vasculaire et métabolique, Centre Intégré de l'obésité, Inserm U1027, CHU de Toulouse, Hôpital Larrey, Toulouse, France
| | - M Barigou
- Pôle Cardio-vasculaire et métabolique, Centre Intégré de l'obésité, Inserm U1027, CHU de Toulouse, Hôpital Larrey, Toulouse, France
| | - H Hanaire
- Pôle Cardio-vasculaire et métabolique, Centre Intégré de l'obésité, Inserm U1027, CHU de Toulouse, Hôpital Larrey, Toulouse, France
| |
Collapse
|
24
|
Barigou M, Kang FA, Orloff E, Amar J, Chamontin B, Bouhanick B. 9B.07. J Hypertens 2015. [DOI: 10.1097/01.hjh.0000467679.09060.cb] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Barigou M, Ah-Kang F, Orloff E, Amar J, Chamontin B, Bouhanick B. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann Cardiol Angeiol (Paris) 2015; 64:169-174. [PMID: 26051856 DOI: 10.1016/j.ancard.2015.04.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2015] [Accepted: 04/28/2015] [Indexed: 06/04/2023]
Abstract
AIMS To study the influence of postural changes on aldosterone to renin ratio (ARR) in patients with suspected secondary hypertension and to evaluate the sensitivity and specificity of the recommended seated ARR compared to supine and upright ARR for primary aldosteronism screening. METHODS Fifty-three hypertensive patients were prospectively hospitalized for secondary hypertension exploration (age: 51 ± 12, 66% males). After withdrawal of drugs interfering with renin angiotensin system, plasma aldosterone and direct renin concentration were measured in the morning, at bed after an overnight supine position, then out of bed after 1 hour of upright position and finally 2 hours later after 15 minutes of seating. Minimal renin value was set at 5 μUI/mL. RESULTS Referring to ARR cut-off of 23 pg/μUI, the sensitivity of seated ARR was 57.1% and specificity was 92.3%. The negative and positive predictive values were 95.1% and 45.2% respectively. Compared to these results, a cut-off of 19 improved sensitivity to 85.7% with a specificity of 89.7%. Negative and positive predictive values were 98.3% and 41.1% respectively. Seated ARR mean value was lower than supine and upright ARR mean values, due to an overall increase in renin at seating compared to the supine position by factor 1.9 while aldosterone just slightly increased by factor 1.2. Seated ARR correlated to supine and upright ARR: correlation coefficients (r) 0.90 and 0.93 respectively (P<0.001). CONCLUSIONS Current recommended measurement of ARR in the seating position is fairly correlated to supine and upright ARR. A suggested cut-off value of 19 instead of 23 pg/μUI increased the discriminating power of this test.
Collapse
Affiliation(s)
- M Barigou
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France.
| | - F Ah-Kang
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - E Orloff
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - J Amar
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - B Chamontin
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - B Bouhanick
- Pôle cardiovasculaire et métabolique, service de médecine interne et hypertension artérielle, hôpital Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| |
Collapse
|
26
|
Eesa M, Barigou M. Enhancing radial temperature uniformity and boundary layer development in viscous Newtonian and non-Newtonian flow by transverse oscillations: A CFD study. Chem Eng Sci 2010. [DOI: 10.1016/j.ces.2009.12.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Pianko-Oprych P, Nienow A, Barigou M. Positron emission particle tracking (PEPT) compared to particle image velocimetry (PIV) for studying the flow generated by a pitched-blade turbine in single phase and multi-phase systems. Chem Eng Sci 2009. [DOI: 10.1016/j.ces.2009.08.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
|
29
|
Chung K, Barigou M, Simmons M. Reconstruction of 3-D Flow Field Inside Miniature Stirred Vessels Using a 2-D PIV Technique. Chem Eng Res Des 2007. [DOI: 10.1205/cherd06165] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
30
|
|
31
|
|
32
|
Hall J, Barigou M, Simmons M, Stitt E. A PIV study of hydrodynamics in gas–liquid high throughput experimentation (HTE) reactors with eccentric impeller configurations. Chem Eng Sci 2005. [DOI: 10.1016/j.ces.2005.03.044] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Hall JF, Barigou M, Simmons MJH, Stitt EH. Just Because It's Small Doesn't Mean It's Well Mixed: Ensuring Good Mixing in Mesoscale Reactors. Ind Eng Chem Res 2005. [DOI: 10.1021/ie050224w] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- J. F. Hall
- Centre for Formulation Engineering, Department of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K., and Johnson Matthey Catalysts, P. O. Box 1, Belasis Avenue, Billingham, Cleveland TS23 1LB, U.K
| | - M. Barigou
- Centre for Formulation Engineering, Department of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K., and Johnson Matthey Catalysts, P. O. Box 1, Belasis Avenue, Billingham, Cleveland TS23 1LB, U.K
| | - M. J. H. Simmons
- Centre for Formulation Engineering, Department of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K., and Johnson Matthey Catalysts, P. O. Box 1, Belasis Avenue, Billingham, Cleveland TS23 1LB, U.K
| | - E. H. Stitt
- Centre for Formulation Engineering, Department of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K., and Johnson Matthey Catalysts, P. O. Box 1, Belasis Avenue, Billingham, Cleveland TS23 1LB, U.K
| |
Collapse
|
34
|
Hall J, Barigou M, Simmons M, Stitt E. Comparative study of different mixing strategies in small high throughput experimentation reactors. Chem Eng Sci 2005. [DOI: 10.1016/j.ces.2004.10.045] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Lim KS, Barigou M. Pneumatic foam generation in the presence of a high-intensity ultrasound field. Ultrason Sonochem 2005; 12:385-393. [PMID: 15590313 DOI: 10.1016/j.ultsonch.2004.05.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2004] [Accepted: 05/04/2004] [Indexed: 05/24/2023]
Abstract
Designer foams find applications in a wide range of industries. Foam quality is mostly determined by its complex cellular structure which defines its texture, rheology and stability. In addition to formulation design, the formation process is crucial to the development of a foam with an optimum structure. There is, therefore, a need for techniques that can assist in the generation of controlled foam structures. The work described in this paper demonstrates the potential of using high-intensity ultrasound to control foam structure during production. Foam generated in the presence of ultrasound usually exhibits a narrower bubble size distribution, i.e. a more uniform texture. Such enhanced homogeneity in texture is desirable to reduce the presence of aesthetically unattractive large cavities, and to reduce the destabilising effects of foam coarsening. In addition, a smaller mean bubble size and a slower rate of foam collapse usually result when ultrasound is applied. The work shows the effects on foams stabilised with different surfactants.
Collapse
Affiliation(s)
- K S Lim
- Department of Chemical Engineering, The University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | | |
Collapse
|
36
|
|
37
|
|
38
|
|
39
|
|
40
|
|
41
|
|
42
|
Kuo HP, Fangary YS, Parker DJ, Barigou M, Seville JPK. Validation of Numerical Simulations of Mixing Using PEPT Experiments. CHEM-ING-TECH 2001. [DOI: 10.1002/1522-2640(200106)73:6<642::aid-cite6421111>3.0.co;2-#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | - D. J. Parker
- Positron Imaging Centre, School of Physics and Space Research, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
| | | | - J. P. K. Seville
- Positron Imaging Centre, School of Physics and Space Research, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
| |
Collapse
|
43
|
|
44
|
|
45
|
|
46
|
Fairhurst P, Barigou M, Fryer P, Pain JP. Particle Passage Time Distributions in Vertical Pipe Flow of Solid–Liquid Food Mixtures. Food and Bioproducts Processing 1999. [DOI: 10.1205/096030899532583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
47
|
Ouazzane A, Barigou M. A Comparative Study of Two Flow Conditioners and Their Efficacy to Reduce Asymmetric Swirling Flow Effects on Orifice Meter Performance. Chem Eng Res Des 1999. [DOI: 10.1205/026387699526728] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
48
|
Abstract
The need to destabilize foams and control their formation arises in many industrial applications. Vibrations are known to affect the structure and rheology of various soft solids but have not been exploited in destroying persistent foams. Being noninvasive, they offer elegant potential alternatives to chemical and mechanical foam breaking techniques. This paper reports an experimental study on the effectiveness of mechanical and ultrasonic vibrations in foam destruction. Mechanical vibration is effective at breaking static foams generated from non-Newtonian shear-thinning liquids, by enhancing liquid drainage and film breakage. Drainage is increased due to enhanced shear thinning that leads to a reduction in yield stress and shear viscosity of the nonNewtonian liquid. High intensity ultrasonic vibration is efficient at destabilizing static foams but is also effective at controlling dynamic foam heads and would be suitable for use in processes that require continuous defoaming. Destabilization of the foam films is attributed to possible squeezing mode surface wave phenomena. Copyright 1999 Academic Press.
Collapse
Affiliation(s)
- MD Morey
- School of Chemical Engineering, The University of Birmingham, Birmingham, Edgbaston, B15 2TT, United Kingdom
| | | | | |
Collapse
|
49
|
Fangary Y, Barigou M, Seville J. Simulation of Yoghurt Flow and Prediction of Its End-of-Process Properties Using Rheological Measurements. Food and Bioproducts Processing 1999. [DOI: 10.1205/096030899532231] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
50
|
|